Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer's disease pharmacogenetics

Current Alzheimer Research

Volumn 4, Issue 4, 2007, Pages 479-500

  Cacabelos, Ramón ^a   Llovo, Ruth ^b   Fraile, Carmen ^a   Fernández Novoa, Lucía ^b  

^a CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^b Centro de Investigacion Biomedica EuroEspes   (Spain)

Author keywords

Alzheimer's disease; APOE; Cholinesterase inhibitors; CYP2D6; Genetics; Genomics; Multifactorial treatment; Pharmacogenetics; Pharmacogenomics

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA SECRETASE ACTIVATOR; APOLIPOPROTEIN E4; BETA SECRETASE INHIBITOR; CASPASE INHIBITOR; CHAPERONE; CHELATING AGENT; CHOLINESTERASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2D6; DONEPEZIL; DOPAMINE UPTAKE INHIBITOR; ENZYME ACTIVATOR; GALANTAMINE; GAMMA SECRETASE INHIBITOR; GROWTH FACTOR; LY 450139; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPEPTIDE; NGX 83232; NICOTINIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; RIVASTIGMINE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ABDOMINAL PAIN; AGITATION; ALZHEIMER DISEASE; ANOREXIA; BRADYCARDIA; CONFERENCE PAPER; DIARRHEA; DIZZINESS; DRUG DISPOSITION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DYSCRASIA; ELECTRON TRANSPORT; FATIGUE; GENE; GENE DUPLICATION; GENOME; GENOTYPE; HUMAN; LIVER DYSFUNCTION; MUSCLE CRAMP; NAUSEA; NERVE DEGENERATION; PATHOGENESIS; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; RISK; SIDE EFFECT; TREATMENT RESPONSE; VOMITING;

EID: 34548671643     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507781788846     Document Type: Conference Paper

References (121)

1. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431: 931-945 (2004).
2. Cacabelos R, Fernández-Novoa L, Lombardi V, Kubota Y, Takeda M. Molecular genetics of Alzheimer's disease and aging. Meth Find Exper Clin Pharmacol 27 (Suppl. A): 1-573 (2005).
3. Cacabelos R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 4(5): 597-621 (2003).
4. Cacabelos R, Alvarez A, Fernández-Novoa L, Lombardi VRM. A pharmacogenomic approach to Alzheimer's disease. Acta Neurol Scand 176(Suppl.): 12-19 (2000).
5. Cacabelos R. Pharmacogenomics in Alzheimer's disease. Min Rev Med Chem 2: 59-84 (2002).
6. Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann Med 34: 357-379 (2002).
7. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nature Rev Genet 5: 645-656 (2004).
8. Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Exp Opin Pharmacother 6(12): 1967-1987 (2005).
9. Cacabelos R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer's disease. Aging Health 1(2): 303-348 (2005).
10. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nature Rev Genet 4: 937-947 (2003).
11. Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 3:67-99 (2002).
12. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nature Genet 39(1): 17-23 (2007).
13. Suh Y-H, Checler F. Amyloid precursor protein, presenilins, and α-synuclein: Molecular pahogenesis and pharmacological applications in Alzheimer's disease. Phamacol Rev 54: 469-525 (2002).
14. Cacabelos R, Fernández-Novoa L, Corzo L, Amado L, Pichel V, Lombardi V, et al. Phenotypic profiles and functional genomics in dementia with a vascular component. Neurol Res 26: 459-480 (2004).
15. th (Eds: Rimoin DL, Connor JM, Pyeritz R, Korf BR). Churchill-Livingstone, Edinburgh, p. 590-631 (2002).
16. Cacabelos R, Fernández-Novoa L, Corzo L, Pichel V, Lombardi V, Kubota Y. Genomics and phenotypic profiles in dementia: Implications for pharmacological treatment. Meth Find Exper Clin Pharmacol 26(6): 421-444 (2004).
17. Motulski AG. From pharmacogenetics and ecogenetics to pharmacogenomics. Med Secoli 14(3): 683-705 (2002).
18. Weinshilboum R. Inheritance and drug response. N Engl J Med 348: 529-537 (2003).
19. Evans WE, McLeod HL. Pharmacogenomics-Drug disposition, drug targets, and side effects. N Engl J Med 348: 538-549 (2003).
20. Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nature Med 10(10): 1055-1063 (2004).
21. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 296: 1991-1995 (2002).
22. Doshi JA, Shaffer T, Briesacher BA. National estimates of medication use in nursing homes: Findings from 1997 Medicare Current Beneficiary Survey and the 1996 Medical Expenditure Survey. J Am Geriatr Soc 53: 438-443 (2005).
23. Percudani M, Barbui C, Fortino I, Petrovich L. Antidepressant drugs prescribing among elderly subjects: a population-based study. Int J Geriat Psychiat 20: 113-118 (2005).
24. Fialová D, Topinková E, Gambassi G, Finne-Soveri H, Johnsson PV, Carpenter I, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 293(11): 1348-1358 (2005).
25. Simon SR, Chan KA, Soumerai SB, Wagner AK, Andrade SE, Feldstein AC, et al. Potentially inappropriate medication use by elderly persons in U.S. Health Maintenance Organizations, 2000-2001. J Am Geriatr Soc. 53: 227-232 (2005).
26. Cacabelos R. Psychogeriatric research. A conceptual introduction to geriatric neuroscience. Psychogeriatrics 1: 158-88 (2001).
27. Cacabelos R, Alvarez XA, Lombardi V, Fernández-Novoa L, Corzo L, Pérez P, et al. Pharmacological treatment of Alzheimer disease: From phychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 36: 415-99 (2000).
28. www.ncbi.nlm.nih.gov/OMIM
29. www.molgen.ua.ac.be/ADMutations/
30. www.mitomap.org/
31. Wright AF, Jaconson SG, Cideciyan AV, Roman AJ, Shu X, Vlachantoni D, et al. Lifespan and mitochondrial control of neurodegeneration. Nature Genet 36: 1153-1158 (2004).
32. Cacabelos R, Fernández-Novoa L, Lombardi V, Corzo L, Pichel V, Kubota Y. Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications. Neurol Res 25: 567-580 (2003).
33. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature Genet 33(Suppl): 245-254 (2003).
34. Hunter DJ. Gene-environment interactions in human diseases. Nature Rev Genet 6: 287-298 (2005).
35. Teter B, Finch CE. Caliban's heritance and the genetics of neuronal aging. Trends Neurosci 27(10): 627-632 (2004).
36. Levenson JM, Sweatt JD. Epigenetic mechanisms in memory formation. Nature Rev Neurosci 6:108-118 (2005).
37. Robertson KD. DNA methylation and human disease. Nature Rev Genet 6:597-610 (2005).
38. Citron M. Strategies for disease modification in Alzheimer's disease. Nature Rev Neurosci 5: 679-685 (2004).
39. Selkoe DJ, Schenk D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43: 545-584 (2003).
40. Golde TE. Alzheimer disease therapy: Can the amyloid cascade be halted? J Clin Invest 111(1):11-18 (2003).
41. Janus C. Vaccines for Alzheimer's disease: how close are we? CNS Drugs 17(7): 457-474 (2003).
42. Michaelis ML. Drugs targeting Alzheimer's disease: Some things old and some things new. J Pharmacol Exper Ther 304:897-904 (2003).
43. Cacabelos R, Lombardi V, Fernández-Novoa L, Kubota Y, Corzo L, Pichel V, et al. A functional genomics approach to the analysis of biological markers in Alzheimer disease. In: Molecular Neurobiology of Alzheimer Disease and Related Disorders. (Eds: Takeda M, Tanaka T, Cacabelos R). Karger, Basel, p. 236-285 (2004).
44. Cacabelos R. Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics 5(8): 1049-1105 (2004).
45. Cacabelos R, Fernández-Novoa L, Pichel V, Lombardi V, Kubota Y, Takeda M. Pharmacogenomic studies with a combination therapy in Alzheimer's disease. In: Molecular Neurobiology of Alzheimer Disease and Related Disorders. (Eds: Takeda M, Tanaka T, Cacabelos R). Karger, Basel, p. 94-107 (2004).
46. Giacobini E. Cholinesterases and cholinesterase inhibitors. Martin Dunitz, London (2000).
47. Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 12(4):295-300 (2001).
48. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer's disease trial. Arch Neurol 60(6): 843-848 (2003).
49. Hogan DB, Goldlist B, Naglie G, Patterson C. Comparison studies of cholinesterase inhibitors for Alzheimer's disease. Lancet Neurol 3: 622-628 (2004).
50. Ferris SH. Evaluation of memantine for the treatment of Alzheimer's disease. Expert Opin Pharmacother 4(12): 2305-2313 (2003).
51. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348(14): 1333-1341 (2003).
52. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54(12): 2261-2268 (2000).
53. Sano M. Economic effect of cholinesterase inhibitor therapy: implications for managed care. Manag Care Interface 17(8): 44-49 (2004).
54. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 21(9): 607-620 (2004).
55. Lyseng-Williamson KA, Plosker GL. Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics 20(13): 919-942 (2002).
56. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 5(1): 1-137 (2001).
57. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363: 2105-2115 (2004).
58. Wimo A. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations. Drug Aging 21(5): 279-295 (2004).
59. Wimo A, Winblad B. Economic aspects on drug therapy of dementia. Curr Pharm Des 10(3): 295-301 (2004).
60. Ward A, Caro JJ, Getsios D, Ishak K, O'Brien J, Bullock E. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in UK. Int J Geriatr Psychiatry 18(8): 740-747 (2003).
61. Evans JG, Wilcock G, Birks J. Evidence-based pharmacotherapy of Alzheimer's disease. Int J Neuropsychopharmacol 7(3): 351-369 (2004).
62. Livingstone G, Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry 19(10): 919-925 (2004).
63. Wimo A, Winblad B, Stoffler A, Wirth Y, Möbius HJ. Resource utilization and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 21(5): 327-340 (2003).
64. Roses AD, Pangalos MN. Drug development and Alzheimer's disease. Am J Geriat Psychiat 11: 123-130 (2003).
65. Stuchbury G, Munch G. Alzheimer's associated inflammation, potential drug targets and future therapies. J Neural Transm 112(3): 429-453 (2005).
66. Lahiri DK. Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene. J Mol Neurosci 23(3): 225-233 (2004).
67. Nitsch RM. Immunotherapy of Alzheimer disease. Alzheimer Dis Assoc Disord 18(4): 185-189 (2004).
68. Harrison T, Churcher I, Beher D. Gamma-secretase as a target for drug intervention in Alzheimer's disease. Curr Opin Drug Discov Devel 7(5): 709-719 (2004).
69. Greig NH, Sambamurti K, Qian-sheng Y, Brossie A, Bruinsma GB, Lahiri DK. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2: 281-290 (2005).
70. Klegeris A, McGeer PL. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2: 355-365 (2005).
71. Meyer UA. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nature Rev Genet 5: 669-676 (2004).
72. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomized double blind placebo controlled trial. BMJ 330(7496): 874 (2005)
73. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence. JAMA 293: 596-608 (2005).
74. Kalow W, Grant DM. Pharmacogenetics. In: The Metabolic & Molecular Bases of Inherited Disease. (Eds: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B). McGraw-Hill, New York, p. 225-255 (2001).
75. Tribut O, Lessard Y, Reymann JM, Allain H, Bentue-Ferrer D. Pharmacogenomics. Med Sci Monit 8: 152-163 (2002).
76. Wedlund P. The CYP2C19 enzyme polymorphism. Pharmacology 61: 174-183 (2000).
77. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60: 284-295 (1997).
78. Isaza CA, Henao J, López AM, Cacabelos R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Meth Find Exp Clin Pharmacol 22: 695-705 (2000).
79. Saito S, Ishida A, Sekine A, Kawauchi S, Higuchi S, Ogawa C, et al. Catalog of 680 variants among eight cytochrome P450 (CYP) genes: nine esterase genes, and two other genes in the Japanese population. J Hum Genet 48: 249-70 (2003).
80. Wooding SP, Watkins WS, Bamshad MJ, Dunn DM, Weiss RB, Jorde LB. DNA sequence variations in a 3.7-kb noncoding sequence 5-prime of the CYP1A2 gene: implications for human population history and natural selection. Am J Hum Genet 71: 528-542 (2002).
81. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 35: 99-106 (2003).
82. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 59: 303-12 (2003).
83. Xie HG, Prasad HG, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic ditribution and functional significance. Adv Drug Deliv Rev 54: 1257-70 (2002).
84. 1) expressed among African Americans. Mol Pharmacol 60: 382-387 (2001).
85. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharm Toxicol 41: 815-50 (2001).
86. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31: 421-31 (2003).
87. Hedlund E, Gustafsson JA, Warner M. Cytochrome P450 in the brain: a review. Curr Drug Metabol 2(3): 245-263 (2001).
88. Evans KL, Muir WJ, Blackwood DHR, Porteus DJ. Nuts and bolts of psychiatric genetics: building on the human genome project. Trends Genet 17: 35-40 (2001).
89. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491 (1999).
90. Arranz MJ, Collier D, Kerwin RW. Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics 1: 3-10 (2001).
91. Poirier J, Delisle M-C, Quirion R, Aubert I, Farlow M, Lahiri D, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits treatment outcome in Alzheimer disease. Proc Natl Acad Sci. USA 92: 12260-12264 (1995).
92. Poirier J. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. J Psychiat Neurosci 24: 147-153 (1999).
93. Almkvist O, Jelic V, Amberla K, Hellstrom-Lindahl E, Meurling L, Nordberg A. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord 12: 22-32 (2001).
94. Sjögren M, Hesse C, Basun H, Kol G, Thostrup H, Kilander L, et al. Tacrine and rate of progression in Alzheimer's disease -relation to ApoE allele genotype. J Neural Transm 108: 451-8 (2001).
95. Borroni B, Colciaghi F, Pastorino L, Archetti S, Corsini P, Cattabeni F, et al. ApoE genotype influences the biological effects of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. Eur Neuropsychopharmacol 12: 195-200 (2002).
96. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2(2): 69-77 (2001).
97. Babic T, Lakusic DM, Sertic J, Petrovecki M, Stavljenic-Rukavina A. ApoE genotyping and response to galanthamine in Alzheimer's disease-a real life retrospective study. Coll Antropol 28(1): 199-204 (2004).
98. MacGowan SH, Wilcock GK, Scott M. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Int J Geriatr Psychiatry 13(9): 625-630 (1998).
99. Rigaud AS, Traykov L, Caputo L, Guelfi MC, Latour F, Courdec R, et al. The apolipoprotein E epsilon 4 allele and the response to tacrine therapy in Alzheimer's disease. Eur J Neurol 7: 255-258 (2000).
100. Rigaud AS, Traykov L, Latour F, Couderc R, Moulin F, Forette F. Presence of absence of least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics 12: 415-20 (2002).
101. Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity, and cerebral perfusion. Meth Find Exp Clin Pharmacol 21: 633-644 (1999).
102. Alvarez XA, Pichel V, Pérez PA, Laredo M, Corzo L, Zas R, et al. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Meth Find Exp Clin Pharmacol 22: 585-594 (2000).
103. Saunders AM, Trowers MK, Shimkets RA, Blakemore S, Crowther DJ, Mansfield TA, et al. The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. Biochem Biophys Acta 1502: 85-94 (2000).
104. Bentué-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 17(13): 947-963 (2003).
105. www.imm.ki.se/CYPalleles/cyp2d6.htm.
106. Griese E-U, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8: 15-26 (1998).
107. Bernal ML, Sinues B, Johansson I, McLellan RA, Wenerholm A, Dahl ML, et al. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 9: 657-660 (1999).
108. Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications. Oncologist 11(2): 126-135 (2006).
109. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger. Elucidation of the genetic basis of the common intermediate metabolizer phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10: 577-581 (2000).
110. Rasmussen JO, Christensen M, Svendsen JM, Skausig O, Hansen EL, Nielsen KA. CYP2D6 gene test in psycgiatric patients and healthy volunteers. Scand J Clin Lab. Invest 66(2): 129-136 (2006).
111. Yamada H, Dahl ML, Viitanen M, Winblad B, Sjoqvist F, Lannfelt L. No association between familial Alzheimer disease and cytochrome P450 polymorphisms. Alzheimer Dis Assoc Disord 12(3): 204-207 (1998).
112. Chen X, Xia Y, Alford M, DeTeresa R, Hansen L, Klauber MR, et al. The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. Ann Neurol 38(4): 653-658 (1995).
113. Cervilla JA, Russ C, Holmes C, Aitchison K, Smith CA, Powell J, et al. CYP2D6 polymorphisms in Alzheimer's disease, with and without extrapyramidal signs, showing no apolipoprotein E epsilon 4 effect modification. Biol Psychiatry 45(4): 426-429 (1999).
114. Atkinson A, Singleton AB, Steward A, Ince PG, Perry RH, McKeith IG, et al. CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy bodies or Alzheimer's disease. Pharmacogenetics 9(1): 31-35 (1999).
115. Nicholl DJ, Bennett P, Hiller L, Bonifatti V, Vanacore N, Fabbrini G, et al. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology 53(7): 1415-1421 (1999).
116. Woo SI, Kim JW, Seo HG, Park CH, Han SH, Kim SH, et al. CYP2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population. Psychiatry Clin Neurosci 55(4): 373-377 (2001).
117. Furuno T, Kawanishi C, Iseki E, Onishi H, Sugiyama N, Suzuki K, et al. No evidence of an association between CYP2D6 polymorphisms among Japanese and dementia with Lewy bodies. Psychiatry Clin Neurosci 55(2): 89-92 (2001).
118. Scordo MG, Dahl ML, Spina E, Cordici F, Arena MG. No association between CYP2D6 polymorphisms and Alzheimer's disease in an Italian population. Pharmacol Res 53(2): 162-165 (2006).
119. Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet 42(15): 1383-1392 (2003).
120. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41(10): 719-739 (2002).
121. Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 32(1): 70-77 (1998).